Incyte

Incyte

Yahoo Finance • 4 days ago

Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?

Spyre Therapeutics SYRE expanded its inflammatory-disease strategy in August with SPY772 and the phase II SKYLIGHT study in hidradenitis suppurativa, or HS. The move takes its combination approach into a new disease area beyond inflammator... Full story

Yahoo Finance • 14 days ago

Stock index futures largely flat after S&P 500 closes at record high

[Wall Street New York stock exchange stock market] alexsl Stock index futures were muted on Friday after the S&P 500 closed at a record high in the previous session. Dow futures (INDU [https://seekingalpha.com/symbol/INDU]) -0.12%, S&P 5... Full story

Yahoo Finance • 27 days ago

1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds

1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds When Wall Street turns bearish on a stock, it's worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms wi... Full story

Yahoo Finance • 30 days ago

US Stock Market Today: S&P 500 Futures Slip As Fed Rate Uncertainty Builds

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. The Morning Bull - US Market Morning Update Wednesday, Jul, 29 2026 US stock futures are mixed in early Tuesday trade, with broad... Full story

Yahoo Finance • last month

Incyte forecasts $5.130B-$5.260B 2026 net sales as Opzelura guidance rises to $1.050B-$1.1B after CMS settlement

Earnings Call Insights: Incyte Corporation (INCY) Q2 2026 MANAGEMENT VIEW * "At the start of the year, we laid out a plan to move Incyte from reliance on a cornerstone product to a company with multiple growth drivers," William Meury (... Full story

Yahoo Finance • last month

Incyte Q2 Revenue Jumps 38%, Raises FY26 Sales Guidance

(RTTNews) - Incyte Corp. (INCY) on Tuesday reported an increase in second-quarter earnings and revenue, driven by strong growth across its commercial portfolio. The company also raised its full-year 2026 sales guidance. Second-quarter net... Full story

Yahoo Finance • last month

Incyte Non-GAAP EPS of $3.09 beats by $0.94, revenue of $1.67B beats by $180M

* Incyte press release [https://seekingalpha.com/pr/20596936-incyte-reports-second-quarter-2026-financial-results-and-provides-business-updates] (INCY [https://seekingalpha.com/symbol/INCY]): Q2 Non-GAAP EPS of $3.09 beats by $0.94. *... Full story

Yahoo Finance • last month

Incyte Q2 Earnings Preview: Can Commercial Growth Sustain A Catalyst-Rich Pipeline?

(RTTNews) - Incyte (INCY), a biopharmaceutical company, is scheduled to report second-quarter financial results on July 28, 2026. Incyte's key therapeutic areas of focus include Haematology, Oncology, Inflammation, and Autoimmunity. In a... Full story

Yahoo Finance • last month

Earnings week ahead: AAPL. MSFT, AMZN, META, XOM, PYPL, CVX, F, KO, ABBV, V, QCOM, BA, MO, SOFI, and more

[Business Person Reviewing Quarterly Report During Meeting in Office Setting] As earnings season reaches one of its busiest and most consequential weeks, investors will be watching a broad lineup of corporate bellwethers spanning technolo... Full story

Yahoo Finance • last month

Halozyme in deal with Incyte to use Enhanze technology for neoplasms candidate

[Businessmen shaking hands] Andy Andrews * Halozyme (HALO [https://seekingalpha.com/symbol/HALO]) has signed a global collaboration and license agreement with Incyte (INCY [https://seekingalpha.com/symbol/INCY]) to potentially use the f... Full story

Yahoo Finance • last month

Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings?

Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings? Incyte has followed the market's trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 8.6% to $114.25 per share while the index has ga... Full story

Yahoo Finance • 2 months ago

2 Fast-Growing Pharmaceutical Stocks to Buy Now

Key Points Incyte has added to its pipeline through acquisitions. It anticipates four new approvals and launches through 2027. TG Therapeutics' shares are up more than 90% so far this year.10 stocks we like better than Incyte › Incyte(NA... Full story

Yahoo Finance • 2 months ago

Lilly, J&J and AbbVie Hit New Highs

This article first appeared on GuruFocus. Healthcare stocks outperformed the broader market on Friday, with Eli Lilly (NYSE:LLY), Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) among the major names hitting fresh 52-week highs. The... Full story

Yahoo Finance • 2 months ago

Lilly, J&J, AbbVie hit new 52-week highs as healthcare outperforms

[Wall Street Stock Market] meshaphoto/E+ via Getty Images Healthcare was a notable outperformer on Wall Street on Friday as several top sector components of the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]), including Eli Lilly... Full story

Yahoo Finance • 2 months ago

Acadia rises as EU backs Rett syndrome therapy

[Diagnosis Rett syndrome and tablets on a wooden table.] designer491 Acadia Pharmaceuticals (ACAD [https://seekingalpha.com/symbol/ACAD]) added ~13% on Friday after an expert panel of the EU drug regulator, the European Medicines Agency,... Full story

Yahoo Finance • 2 months ago

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failed AD, the most... Full story

Yahoo Finance • 2 months ago

Stocks Mostly Lower on Weakness in Megacap Tech and Software Stocks

The S&P 500 Index ($SPX) (SPY) on Monday closed down -0.37%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.29%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.19%.  September E-mini S&P futures (ESU26) fell -0.34%, and... Full story

Yahoo Finance • 2 months ago

Mirum and Incyte's zilurgisertib shows positive Phase 2 data in FOP

Shares of Mirum Pharmaceuticals (MIRM [https://seekingalpha.com/symbol/MIRM]) and Incyte (INCY [https://seekingalpha.com/symbol/INCY]) are in focus after the companies delivered positive pivotal Phase 2 data for their oral FOP candidate, z... Full story

Yahoo Finance • 2 months ago

Key deals this week: GSK, Incyte, Ingredion, OpenAI, and more

[M A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] fengdr Here's a list of key deals reported across sectors this week: Roku Inc. (ROKU [https://seekingalpha.com/symbol/ROKU]) soared 20% on a report t... Full story

Yahoo Finance • 3 months ago

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session... Full story